This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SALT LAKE CITY, Nov. 20, 2013 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) today announced a research collaboration with BioMarin that will use Myriad's novel HRD (Homologous Recombination Deficiency) test to identify tumor types that may be sensitive to BioMarin's investigational product candidate, BMN-673. Specific terms of the deal were not disclosed.
"The biology of cancer is complicated, and while the analysis of multiple gene targets may identify a subset of patients who will respond to PARP inhibitors, we need a more comprehensive test capable of identifying all patients who may benefit from treatment with PARP inhibitors or DNA damaging agents," said Jerry Lanchbury, Ph.D., chief scientific officer at Myriad. "While it is impossible to predict all of the genetic causes of DNA repair deficiency, our HRD test solves this problem by measuring the ultimate effect, which presents as a DNA scar."
Today's agreement marks the second research collaboration between the partners. In October, BioMarin announced the use Myriad's BRAC
Analysis® test in connection with its pivotal Phase 3 clinical study of BMN-673 for breast cancer.
"We look forward to partnering with Myriad and accessing their expertise in developing this assay," said Len Post, chief scientific officer at BioMarin. "Myriad's HRD assay has the potential to complement the development of our PARP inhibitor BMN 673 to identify cancer patients who are most likely to benefit from the therapy."
About Myriad's HRD Test
Myriad's proprietary HRD test detects when a tumor has lost the ability to repair double-stranded DNA breaks resulting in increased susceptibility to DNA-damaging drugs. High HRD scores are prevalent in all breast cancer subtypes and most other major cancers. In previously published data, Myriad's HRD test predicted drug response to platinum therapy in triple-negative breast cancer patients. It is estimated that 490,000 people in the United States who are diagnosed with cancers annually are candidates for treatment with DNA-damaging agents. In March 2013, Myriad announced its first commercial HRD collaboration. Under that prior agreement, Myriad will conduct HRD testing on patients enrolled in PharmaMar's Phase 2 study of PM1183.